Targeting Thyroid Cancer Microenvironment: Basic Research and Clinical Applications

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters.

<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Published Version</td>
<td>doi:10.3389/fendo.2013.00167</td>
</tr>
<tr>
<td>Accessed</td>
<td>May 17, 2018 2:43:16 PM EDT</td>
</tr>
<tr>
<td>Citable Link</td>
<td><a href="http://nrs.harvard.edu/urn-3:HUL.InstRepos:11879177">http://nrs.harvard.edu/urn-3:HUL.InstRepos:11879177</a></td>
</tr>
<tr>
<td>Terms of Use</td>
<td>This article was downloaded from Harvard University's DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at <a href="http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA">http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA</a></td>
</tr>
</tbody>
</table>

(Article begins on next page)
Targeting thyroid cancer microenvironment: basic research and clinical applications

Carmelo Nucera*

Human Thyroid Cancers Preclinical and Translational Research Laboratory, Experimental Division of Cancer Biology and Angiogenesis, Department of Pathology, Beth Israel Deaconess Medical Center, Simon C. Fireman Research Center, Harvard Medical School, Boston, MA, USA

*Correspondence: cnuce@bidmc.harvard.edu; carmmuce@libero.it

Edited by: Antonino Belfiore, University Magna Graecia of Catanzaro, Italy

Keywords: thyroid cancer, microenvironment, BRAF

INTRODUCTION

Thyroid cancer is the most common endocrine malignancy and its incidence has increased considerably over the past few decades (1). This Research Topic is devoted to understanding the molecular mechanism of human thyroid cancer, with an emphasis on translation to the clinic. The original research papers assembled here probe the pathogenetic pathway from a wide range of approaches, including: (1) the role of microenvironment in thyroid cancer, (2) the role of deiodinases and epigenes leading to thyroid cancer, (3) functional studies of genetic mutations that shed insights into the etiology and pathogenesis of papillary thyroid micro-carcinoma or carcinoma (PTC), (4) genome-wide studies that describe patho-physiological mechanisms for thyroid cancer, and (5) epidemiological studies of thyroid cancer incidence and (6) the influence of environmental factors on development of human PTC.

SCOPE

The articles gathered here reflect a particular interest in the genetic and epigenetic factors that could affect the thyroid cancer cell and its microenvironment. In particular, this topic will present preclinical and clinical research addressing the following issues: (i) identification of specific molecular patterns of thyroid tumorigenesis and tumor microenvironment, which could suggest new directions in pharmacotherapy research; (ii) discovery of new biomarkers to predict response or resistance to drug treatment, facilitating targeted cancer therapies and patient follow-up after treatment; (iii) discovery of environmental risk factors that might affect PTC development; and (iv) evaluation of preclinical models of human thyroid cancers with regard to their suitability for testing new drugs and molecule-targeted agents and for studies of targetable mechanisms of oncogenesis, malignant progression, and metastatic disease.

Specific areas of investigation in this topic include the following as they relate to thyroid cancer: epidemiology and clinical research; epigenetics in thyroid; personalized medicine in thyroid; the tumor microenvironment; novel applications of bioinformatics in human thyroid cancer cell lines; molecular characterization of thyroid tumors; and use of diagnostic and prognostic biomarkers.

WHY IS TARGETING THE THYROID CARCINOMA MICROENVIRONMENT TRANSLATIONAL?

Currently no successful treatment is available for advanced thyroid cancer, including poorly differentiated (PTC), anaplastic/undifferentiated (ATC), and metastatic recurrent/persistent differentiated PTC that is not responsive to radio-iodine therapy.

The past decade of thyroid cancer research has yielded fundamental advances with profound translational potential. Identification of molecular markers, including oncogenes (e.g., the BRAFV600E mutation), tumor suppressors (e.g., TP53 mutations), and translocations (e.g., RET/PTC, PAX8/PPARγ), have clarified molecular mechanisms underlying the pathogenesis of thyroid cancer. However, correlations between each biomarker and prognosis/outcome have not yet been determined in a broad cohort of patients with metastatic thyroid cancer. Currently, BRAFV600E is the most frequent genetic hallmark of PTC and has been highlighted as a prognostic biomarker to improve risk stratification of patients with PTC, including low risk PTC (2–7). Recently, a retrospective multicenter study has also shown that the occurrence of the BRAFV600E mutation was significantly associated with increased cancer-related mortality among patients with PTC. However, because mortality in patients with PTC was low and the association was not independent of PTC clinicopathologic features, the role of BRAFV600E as marker of mortality risk in patients with PTC remains to be determined (3).

Preclinical studies have shown that PTC carrying the BRAFV600E mutation are dependent on this oncoprotein for viability; both genetic and pharmacological inhibition of BRAFV600E expression or activity is associated with thyroid carcinoma regression and restoration of radio-iodine uptake in vivo in mice (8). Furthermore, BRAFV600E plays an important role in PTC progression to ATC through genes fundamental in the regulation of tumor microenvironment by triggering tumor invasion and metastasis (9). Therefore, testing a patient’s thyroid cancer for BRAFV600E will yield important information about potential tumor aggressiveness and inform future use of targeted therapies with selective BRAFV600E inhibitors. Collectively, these findings suggest a potential translational application for anti-BRAFV600E
microenvironment-specific targets of thyroid carcinoma are a
Frontiers in Endocrinology

cytes and high FoxP3
human thyroid cancers. For example, tumor-associated lympho-
tory to radio-iodine treatment and surgically inoperable thyroid
therapy in clinical trials for patients with thyroid cancers refrac-
tory to radio-iodine treatment and surgically inoperable thyroid
cancers.

BRAFV600E affects the expression of tumor extracellular matrix
(ECM) non-cellular components (e.g., Thrombospondin-1 (TSP-
1), integrins and others) by regulating PTC cell microenviron-
ment communications; indeed, the molecular action of BRAFV600E
appears to affect both the migratory and invasive properties of
the human thyroid cancer cell itself, as well as other cell
types of the thyroid tumor microenvironment. Knowledge about
new BRAFV600E-dependent targets may help identify
secreted factors that could serve as novel prognostic biomarkers
and/or innovative therapeutic strategies in BRAFV600E-positive
human thyroid cancers. For example, tumor-associated lympho-
cyes and high FoxP3(+) regulatory T cell (Treg) frequency in
primary PTC correlates with more aggressive disease. This
suggests Treg frequency could be a predictive factor in
PTC and that the suppressive effects of Treg could be consid-
ered in the design of immune-based therapies in PTC. Also,
Ryder et al. found that tumor-associated macrophages (TAMs)
may facilitate thyroid cancer progression, showing that the
presence of a high density of TAMs in advanced metastatic
thyroid cancers correlates with invasion and decreased cancer-related
survival.

In summary, novel therapeutic strategies that target the
metastatic thyroid carcinoma microenvironment (i.e., ECM cell-
ular and non-cellular components) could offer an additional
approach to the treatment of patients with these types of can-
cers. Targeting other cell types in the microenvironment instead
of, or in addition to, the BRAFV600E-positive metastatic thyroid
cancer cell might also minimize anti-BRAFV600E drug resistance
and provide potential additional therapeutic benefits. Determin-
ing the effects of factors in the thyroid tumor microenvironment
will further define the spectrum of molecular mechanisms under-
lying signaling in metastatic thyroid carcinomas. Understanding
the extent to which microenvironment factors participate in the
aberrant behavior of BRAFV600E-positive human metastatic thyroid
cancer cells will reveal whether the microenvironment is a
promising target for development of new therapies. In summary,
current research suggests that novel therapies directed against
“microenvironment-specific targets” of thyroid carcinoma are a
promising approach and should be developed and tested in pre-
clinical/translational models of human metastatic thyroid cancer
in the near future.

ACKNOWLEDGMENTS

This work was supported by Carmelo Nucera (Principal Investi-
gator, Program: Human Thyroid Cancers Preclinical and Trans-
lational Research) funded by the National Institutes of Health
Grants NIH21CA165039 (to Carmelo Nucera) and the Amer-
ican Thyroid Association (ATA) for the Thyroid Cancer Research
Grant. Carmelo Nucera was also recipient of the Guido Berlucchi
research award (Brescia, Italy).

REFERENCES

1. Ito Y, Nikiforov YE, Schlumberger M, Vigneri R. Increasing incidence of thy-
doi:10.1038/nrendo.2012.257

2. Xing M, Haugen BR, Schlumberger M. Progress in molecular-based man-
doi:10.1016/S0140-6736(13)60109-9

ation between BRAF V600E mutation and mortality in patients with papillary

4. Nucera C, Pontecorvi A. Clinical outcome, role of BRAF(V600E), and mole-
cular pathways in papillary thyroid microcarcinoma: is it an indolent cancer
or an early stage of papillary thyroid cancer? Front Endocrinol (2012) 3:33.
doi:10.3389/fendo.2012.00033

bined molecular-pathologic score improves risk stratification of thyroid papil-

sonographic clinical profile, cytology, and BRAF V600E mutation evaluation in
thyroid nodule screening for malignancy: a prospective study. J Clin Endocrinol

7. Mekel M, Nucera C, Hodin RA, Parangis S. Surgical implications of B-RafV600E

8. Chakravarty D, Santos E, Ryder M, Knauf JA, Liao XH, West BL, et al. Small-
molecule MAPK inhibitors restore radiodiode incorporation in mouse thyroid
doi:10.1172/JCI46382

Raf(V600E) and thrombospondin-1 promote thyroid cancer progression. Proc

Targeting BRAFV600E with PLX4720 displays potent antimigratory and anti-
nvasive activity in preclinical models of human thyroid cancer. Oncology

El, et al. Relief of feedback inhibition of HER3 transcription by RAF and MEK
inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcino-

12. French JD, Weber ZJ, Fretwell DL, Said S, Kloor J, Haugen BR. Tumor-
associated lymphocytes and increased FoxP3+ regulatory T cell frequency cor-
relate with more aggressive papillary thyroid cancer. J Clin Endocrinol Metab

death-1+ T cells and regulatory T cells are enriched in tumor-involved lymph
nodes and associated with aggressive features in papillary thyroid cancer. J

14. Ryder M, Ghasseim RA, Ricarte-Filho JC, Knauf JA, Fagin JA. Increased
density of tumor-associated macrophages is associated with decreased sur-
doi:10.1677/ERC-08-0036

Received: 15 October 2013; accepted: 22 October 2013; published online: 04 November
2013.

Citation: Nucera C (2013) Targeting thyroid cancer microenvironment: basic research

This article was submitted to Cancer Endocrinology, a section of the journal Frontiers in
Endocrinology. Copyright © 2013 Nucera. This is an open-access article distributed under
the terms of the Creative Commons Attribution License (CC BY). The use, distribution or repro-
duction in other forums is permitted, provided the original author(s) or licensor are
credited and that the original publication in this journal is cited, in accordance with
accepted academic practice. No use, distribution or reproduction is permitted which
does not comply with these terms.